Valneva SE Sponsored ADR
Valneva SE Sponsored ADR is an American depositary receipt representing shares of Valneva SE, a specialty vaccine company focused on the development, manufacture, and commercialization of prophylactic vaccines for infectious diseases with unmet medical needs. Valneva’s current portfolio includes vaccines for travel and endemic disease prevention, serving public health, travel medicine, and infectious disease markets. The company works across research, clinical development, manufacturing, and commercialization, giving it an integrated role in bringing vaccines from development to market. Its business is centered on specialty immunization products designed for targeted patient groups and healthcare providers, with a focus on prevention rather than treatment. Valneva SE is headquartered in Saint-Herblain, France.
$5.61
-$0.30 (-5.08%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-46.74% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 3.0%, essentially flat. This is a business that needs a catalyst.
Negative free cash flow of -€57M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€143M
▲ +3.0% YoY
Net Income (TTM)
-€158M
▼ -840.6% YoY
Op. Margin
-80.39%
▼ -0.9pp YoY
ROIC
-18.14%
▼ -1.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€58M
▲ +31.4% YoY
Op. Cash Flow (TTM)
-€56M
▼ -274.3% YoY
Net Debt
€98M
Cash & Equiv.
€110M
3Y CAGR: -21.5%
Continue Research
Is Valneva SE Sponsored ADR (VALN) overvalued?
Valneva SE Sponsored ADR (VALN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Valneva SE Sponsored ADR scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Valneva SE Sponsored ADR a high-quality business?+
Valneva SE Sponsored ADR scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -80.4% operating margin and a -18.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Valneva SE Sponsored ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh VALN's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.